Tesamorelin / Ipamorelin

Tesamorelin/Ipamorelin is a vendor name for two peptides in one vial: tesamorelin, an FDA-approved GHRH analogue sold as Egrifta, and ipamorelin, an unapproved ghrelin-receptor agonist. Unlike most blends on this site, one component here is a real, approved drug, but that doesn’t make the combination approved; a fixed-dose combination needs its own dose-ranging and stability data, and none exists for this pair. An FDA warning letter documents one specific marketed version at a 10:3 mg ratio. No study of the combination exists in any species, and the tesamorelin dose commonly circulating for this blend is the same dose that failed in tesamorelin’s own clinical trials.

Ask about Tesamorelin + ipamorelin combination

Research snapshot

Peptide categoryTwo-component peptide blend (one FDA-approved GHRH analogue + one unapproved ghrelin receptor agonist)
Primary research interestGrowth hormone axis stimulation (marketed; not established for this combination)
Highest available evidenceTier 5 for the combination: each component has its own separate evidence base; the combination has none
Human research availableNo: zero studies of the combination exist or are registered (confirmed via direct ClinicalTrials.gov and PubMed search)
Development statusNot a formulated drug product; a compounding/vendor mixture
Regulatory statusTesamorelin alone is FDA-approved for a different indication and route of marketing; this combination is not approved for any use and has been the subject of federal enforcement action

Technical identity (composition)

Primary nameTesamorelin/Ipamorelin blend (vendor name)
CompositionTesamorelin (FDA-approved GHRH analogue) + ipamorelin (unapproved, selective ghrelin receptor agonist)
Share of vial by massGenerally 2:1 to 4:1, tesamorelin-heavy; one FDA warning letter documents a real marketed product at 10 mg tesamorelin to 3 mg ipamorelin (~3.3:1)
Peptide sequenceNot applicable: a multi-component mixture; see individual Tesamorelin and Ipamorelin pages for each molecule’s sequence
Molecular formulaNot applicable: a multi-component mixture, not a single molecular entity
CAS Registry NumberNot applicable: no CAS number is assigned to the combination itself
Chemical modificationsNot applicable at the combination level; see individual component pages
Developer or originatorNot applicable: a vendor-mixed blend, not a developed drug product (tesamorelin itself was developed by Theratechnologies)
Development statusNot in formal development as a combination; no INN, no approved combination status

What it is

Tesamorelin / ipamorelin is a vendor name for two peptides in one vial: tesamorelin, an FDA-approved GHRH analogue sold as Egrifta, and ipamorelin, an unapproved, selective ghrelin-receptor agonist. Unlike CJC-1295 / ipamorelin, one half of this pair is a real drug with a real label. That does not make the blend approved; a fixed combination needs its own dose-ranging and stability data, and none exists for this pair.

What is actually in the vial

Circulating descriptions put the combined vial at roughly 9, 13 or 15 mg total, with tesamorelin to ipamorelin ratios generally in the region of 2:1 to 4:1, tesamorelin-heavy, for example a 9 mg vial described as 6 mg tesamorelin plus 3 mg ipamorelin. That is a different convention from CJC-1295 / ipamorelin, where the dominant split is closer to equal weight.

One instance of this exact product is documented in a primary regulatory source rather than inferred from vendor copy. An FDA warning letter to Royal Peptides LLC, dated 24 August 2026, names a product marketed as BIMORELIN and describes it as “Tesamorelin (10 mg) and Ipamorelin (3 mg),” a ratio of roughly 3.3:1. That is the most concrete composition figure available for this blend, precisely because it comes from an enforcement document rather than a listing.

What one injection delivers, and why that is harder to say here than for other blends

For CJC-1295 / ipamorelin, once the split and the reconstitution volume are known, the milligrams per injection follow from arithmetic. For this blend that same arithmetic runs into a wall: circulating blend material describes the product by combined total peptide weight and does not state how much tesamorelin a single injection is meant to deliver. That is not a gap this entry can fill by calculation, because the vial’s per-dose intent, as distinct from its total content, is not published anywhere reviewed for this entry.

That matters specifically for tesamorelin, because its label requires monitoring against a known dose: glucose status before starting, periodic glucose monitoring during treatment, and IGF-1 monitoring with a stated discontinuation threshold. None of that is structurally possible against a vial where the tesamorelin content of a single dose is not stated.

What has actually been tested

No study of tesamorelin and ipamorelin administered together, in any species, was located for this entry. A ClinicalTrials.gov search for the intervention “tesamorelin AND ipamorelin” returned zero registered trials, and a PubMed search for “tesamorelin ipamorelin combination growth hormone” returned zero results. Each peptide has its own separate human trial record, covered on its own entry, and neither trial record involves the other compound.

Potential benefits and research applications

Growth hormone axis stimulation and body composition (the marketed premise)

What is being investigated: nothing specific to this combination, no study exists. How the effect might occur: by combining tesamorelin’s GHRH-pathway effect (established for visceral fat reduction in its approved population) with ipamorelin’s ghrelin-pathway effect. Evidence: none for the combination; tesamorelin’s own approved effect is narrow (visceral fat in HIV-lipodystrophy specifically, not general body composition) and ipamorelin’s own trial record is negative. Strength: not established. Limitation: even setting aside the lack of combination data, using tesamorelin outside its approved population and indication is itself off-label with no supporting trial data of its own.

Reading tesamorelin’s own dose against the blend

This is the one finding on this page worth sitting with, because it runs the opposite direction from most blends reviewed on this site. Circulating aggregate figures put the tesamorelin component of blended protocols at around 2 mg subcutaneously once daily, but separate circulating material for tesamorelin used on its own, outside a blend, commonly centres closer to 1 mg per day. Set either figure against the approved record and the comparison is unusually direct: EGRIFTA is dosed at 2 mg per day, EGRIFTA SV at 1.4 mg per day and EGRIFTA WR at 1.28 mg per day. A circulating figure of 1 mg per day sits below every approved dose ever marketed for this drug.

It is not simply a low dose. In the phase 2 dose-ranging trial that selected 2 mg per day for the pivotal programme, the 1 mg arm did not separate from placebo on visceral fat or trunk fat, the two measures the drug is approved to treat; only the 2 mg arm reached significance. So where the usual finding on this site is a circulating dose that exceeds anything studied, tesamorelin’s own approved-drug record contains a specific instance of a dose that was tried, in a controlled trial, at roughly the figure that circulates for this component, and it missed its endpoint.

The 1 mg figure is not fabricated or arbitrary either; it was used for 20 weeks in a separate cognition trial, and it was the pre-specified dose-reduction level in a hepatic-fat trial protocol. It is a real dose from the tesamorelin record. It is simply attached, in circulating material, to a use it did not succeed at when it was actually tested at that level.

What dosage information circulates?

Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.

Reported use or research objectiveRoute reportedAmount reportedFrequency reportedReported durationEvidence or source category
GH axis stimulation, blendSubcutaneousCombined vial dosed by volume; tesamorelin content per dose not statedOnce daily, usually evening8–12 weeks, then a breakCommunity/vendor reported
Tesamorelin component, aggregate figureSubcutaneousAbout 1–2 mgOnce daily8–12 weeksCommunity/vendor reported
Ipamorelin componentSubcutaneousA few hundred mcgOnce daily, usually morning8–16 weeks, then a breakCommunity/vendor reported
Documented marketed product (BIMORELIN)Not specified (vial contents only)10 mg tesamorelin + 3 mg ipamorelin (vial total, not per-dose)Not specifiedNot specifiedFDA enforcement document

The commonly circulating tesamorelin figure (~1 mg/day) is the same dose that did not separate from placebo on visceral or trunk fat in tesamorelin’s own Phase 2 dose-ranging trial, the trial that led the pivotal program to use 2 mg instead. Most vendor listings state only combined vial weight, not per-injection tesamorelin content, so a person using this blend generally cannot determine their actual dose, which also makes tesamorelin’s label-required glucose and IGF-1 monitoring difficult to apply meaningfully.

Regulatory status

Tesamorelin is FDA-approved as Egrifta for HIV-associated lipodystrophy, and its label requirements (glucose and IGF-1 monitoring) apply to that approved product at its approved dose, not to any blend. This blend, as a fixed combination, has no approval of its own. Ipamorelin has no approval anywhere: it was nominated for the 503A compounding list, that nomination was withdrawn, and the Pharmacy Compounding Advisory Committee voted twelve to zero against both the free base and the acetate on 29 October 2024. WADA names ipamorelin directly in section S2.2.4, growth hormone secretagogues, prohibited at all times.

The Royal Peptides LLC warning letter cited above is itself the clearest regulatory fact this entry can offer: a named, marketed product combining these two compounds at a stated ratio was the subject of federal enforcement action in 2026.

Frequently asked questions

What is the Tesamorelin/Ipamorelin blend?

A vendor product combining FDA-approved tesamorelin with unapproved ipamorelin, typically at a tesamorelin-heavy ratio (2:1 to 4:1).

Is this blend FDA approved?

No. Tesamorelin alone is approved for one specific indication; the combination product itself is not approved for any use.

Has the combination been studied?

No, confirmed by direct search of ClinicalTrials.gov and PubMed, which return zero results for the combination.

How much tesamorelin am I actually injecting?

This can’t be determined from most vendor listings, which state only combined vial weight, not per-injection tesamorelin content.

Is there a documented real-world example of this product?

Yes. An FDA warning letter names a specific marketed version (“BIMORELIN”) at 10 mg tesamorelin to 3 mg ipamorelin.

Why does the circulating tesamorelin dose matter?

Because the commonly used about-1-mg-per-day figure is the exact dose that failed to separate from placebo in tesamorelin’s own phase 2 trial.

Can I do the label-required IGF-1 monitoring on this blend?

Not meaningfully, since you generally can’t determine your actual per-injection tesamorelin dose from the vial.

Is ipamorelin approved for any use?

No, see its own entry for the 2024 unanimous advisory committee vote against it.

What remains unknown?

Nearly everything about the combination specifically: whether it does anything beyond tesamorelin alone, whether the two peptides are stable together, and what per-injection dose any given vial actually delivers.

Bottom line

This blend pairs one real, FDA-approved drug with one unapproved compound, but that pairing doesn’t inherit tesamorelin’s approval, and it actively undermines tesamorelin’s own safety framework, since the label’s required glucose and IGF-1 monitoring depends on knowing the actual dose, which most vendor listings don’t disclose. The tesamorelin dose that does circulate for this blend isn’t a conservative choice; it’s the specific dose that failed in the trial that determined tesamorelin’s approved dosing. No study of the combination exists in any species, and the clearest documentation of what an actual marketed product contains comes not from a vendor but from a federal enforcement letter.

Reported amounts and the evidence behind them: Ipamorelin dosage: what the trials and online protocols report.

What circulates E5

Figures reported online. Not dosing, not verified, not endorsed.
Reported useRouteAmount reportedFrequencyReported length
Growth hormone axis stimulation, blendSubcutaneousDosed by volume; per-injection content not statedOnce daily, usually in the evening8 to 12 weeks, then a break
Tesamorelin component, aggregate figureSubcutaneousAround 1 to 2 mgOnce daily8 to 12 weeks
Ipamorelin componentSubcutaneousA few hundred microgramsOnce daily, usually in the morning8 to 16 weeks, then a break

The tesamorelin component of this blend is the sharpest comparison on this site between a circulating figure and an approved drug's own tested record. EGRIFTA is dosed at 2 mg per day, EGRIFTA SV at 1.4 mg and EGRIFTA WR at 1.28 mg. A circulating figure of 1 mg per day, which appears for tesamorelin both alone and as the blend component, sits below every one of those approved doses.

That figure is not simply low, it is a dose that was tried and did not work for the approved indication: in the phase 2 dose-ranging trial that selected 2 mg for the pivotal programme, the 1 mg arm did not separate from placebo on visceral or trunk fat, the two measures the drug treats. Only the 2 mg arm reached significance.

For the ipamorelin component, no human dose comparison is possible at all, because the only dose of ipamorelin ever given to a human in a published trial was intravenous, not subcutaneous, and that trial missed its own endpoint.

None of the circulating material reviewed for this entry states the tesamorelin content of a single injection, which means a person using this blend cannot check their own dose against either the approved record or the failed dose-ranging arm above, because they do not know which one they are closer to.

Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.

Research area: Growth hormone axis.

Share thisFacebookXEmail